Research Projects & Grants

Federal

  • COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones, Role: Investigator, Children Oncology Group, (07/2024 - 07/2025) Status: Approved
  • COG ACNS1422: A Phase 2 Study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients, Role: Investigator, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
  • COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS), Role: Investigator, Children Oncology Group, (03/2025 - 03/2026) Status: Approved
  • COG AEWS1221: Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab (AMG 479, NSC# 120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid, Role: Investigator, Children Oncology Group, (02/2025 - 02/2026) Status: Approved
  • Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - AEWS1031: A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-AAML1031: A phase III randomized trial for patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for patients with high allelic ratio FLT3/ITD, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy), Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG: AALL0434 - Intensified methotrexate, nelarabine (compound 506U78; IND# 52611) and augmented BFM therapy for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-Cell Lymphoblastic Lymphoma, Role: Investigator, Children Oncology Group, (01/2025 - 03/2025) Status: Completed
  • COG- AHOD0831: A non-randomized phase III study of response adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin's Lymphoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-AAML0631:Risk adapted treatment of newly diagnosed childhood Acute Promyelocytic leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during consolidation, Role: Investigator, Children Oncology Group, (01/2015 - 01/2016) Status: Completed
  • COG-ANBL 12P1: pilot study using myeloblative Busulfan/Melphalan (BuMel) consolidation following induction chemotherapy for patients with newly diagnosed high-risk neuroblastoma, Role: Investigator, Children Oncology Group, (06/2014 - 06/2015) Status: Completed
  • Childrens Oncology Group (COG) - ACNS0822: A randomized phase II/III study of vorinostat and local irradiation or temozolomide and local irradiation or bevacizumab and local irradiation followed by maintenance bevacizumab and temozolomide in children with newly diagnosed high-grade gliomas, Role: Investigator, Children Oncology Group, (04/2014 - 04/2015) Status: Completed
  • COG - AALL1122/BMS - CA180-372: A phase 2 multi-center historically-controlled study of dasatinib added to standard chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL), Role: Investigator, Children Oncology Group, (11/2013 - 11/2014) Status: Completed
  • Children's Oncology Group (COG) - COG - ARST0921: a randomized phase II trial of bevacizumab (avastin) and temsirolimus (torisel) in combination with intravenous vinorelbine and cyclophosphamide in patients with recurrent/refractory rhabdomyosarcoma, Role: Investigator, Children Oncology Group, (09/2013 - 09/2014) Status: Completed
  • Children's Oncology Group (COG) Protocol #ACNS0232: Radiotherapy alone versus chemotherapy followed by response-based radiotherapy for newly diagnosed primary CNS germinoma, Role: Investigator, Children Oncology Group, (07/2008 - 07/2009) Status: Completed

For Profit Organization

  • SWOG 9508. A phase III study comparing three cycles of infusional BCNU/Cisplatin followed by radiation therapy with tadiation therapy and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme, Role: PI, Southwest Oncology Group, (08/1999 - 08/2000) Status: Completed

Internal

  • Phase I-II trial of stereotactic body proton therapy for patients with liver metastases, Role: Investigator, LLU Dept. of Radiation Medicine, (08/2024 - 08/2025) Status: Approved
  • Radiation medicine research registry, Role: Investigator, LLU Dept. of Radiation Medicine, (10/2024 - 09/2025) Status: Approved
  • Outcomes of Pediatric Patients with Brain Arteriovenous Malformation treated with Proton Beam Radiation Therapy, Role: PI, LLU Dept. of Radiation Medicine, (02/2021) Status: Approved
  • Clinical outcomes of orbital rhabdomyosarcoma and retinoblastoma, Role: PI, LLU Dept. of Radiation Medicine, (02/2020) Status: Approved
  • CT and MR imaging patterns of chordoma and chondrosarcoma of the brain and spine, Role: Investigator, LLU Dept. of Radiology, (06/2012 - 06/2013) Status: Completed

Non-Profit Organization

  • NSABP B51 / RTOG 1304: a randomized phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (09/2024 - 09/2025) Status: Approved